Fig. 1
From: TROP2-directed nanobody-drug conjugate elicited potent antitumor effect in pancreatic cancer
Screening of anti-TROP2 nanobody. A Schematic illustration of the screening of TROP2-targeted nanobodies. B The affinity of TROP2 nanobody candidates for TROP2 protein was determined by ELISA. C Binding activity of TROP2 nanobody candidates to TROP2-expressing cells was assessed by flow cytometry. D Cells were incubated with nanobody candidates and the fluorescently labeled secondary antibodies, and the internalization of nanobodies was determined by measuring intracellular fluorescence intensity through flow cytometry